PAVM Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of 12.65%. PAVmed, Inc.'s return on equity of 8.75% beat Electromed, Inc.'s return on equity of 18.89%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2495.63%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.48%. Given that PAVmed, Inc. has higher upside potential than Electromed, Inc., analysts believe PAVmed, Inc. is more attractive than Electromed, Inc..

PAVmed, Inc. has a beta of 1.106, which suggesting that the stock is 10.577% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. PAVmed, Inc.'s net income of -$6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Electromed, Inc.'s PE ratio is 29.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 5,129.46x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -12.6%. PAVmed, Inc.'s return on equity of 8.75% beat IRIDEX Corp.'s return on equity of -155.93%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2495.63%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 34.23%. Given that PAVmed, Inc. has higher upside potential than IRIDEX Corp., analysts believe PAVmed, Inc. is more attractive than IRIDEX Corp..

PAVmed, Inc. has a beta of 1.106, which suggesting that the stock is 10.577% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.529, suggesting its less volatile than the S&P 500 by 47.142%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than IRIDEX Corp. quarterly revenues of $12.5M. PAVmed, Inc.'s net income of -$6M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 5,129.46x versus 0.49x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -36.3%. PAVmed, Inc.'s return on equity of 8.75% beat Myomo, Inc.'s return on equity of -68.35%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2495.63%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 420.83%. Given that PAVmed, Inc. has higher upside potential than Myomo, Inc., analysts believe PAVmed, Inc. is more attractive than Myomo, Inc..

PAVmed, Inc. has a beta of 1.106, which suggesting that the stock is 10.577% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. PAVmed, Inc.'s net income of -$6M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 5,129.46x versus 0.95x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -86.59%. PAVmed, Inc.'s return on equity of 8.75% beat Stereotaxis, Inc.'s return on equity of -218.3%.

PAVmed, Inc. has a consensus price target of $9.50, signalling upside risk potential of 2495.63%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 53.85%. Given that PAVmed, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe PAVmed, Inc. is more attractive than Stereotaxis, Inc..

PAVmed, Inc. has a beta of 1.106, which suggesting that the stock is 10.577% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.445, suggesting its more volatile than the S&P 500 by 44.465%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. PAVmed, Inc.'s net income of -$6M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 5,129.46x versus 8.05x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.